NCT04786262
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
Recruiting
PHASE3Ages 18–65InterventionalTreatmentVertex Pharmaceuticals Incorporated
~57 participants
Updated 2026-09-01 on ClinicalTrials.gov
What's tested:VX-880VX-017
At a glance
Recruiting sites
26 of 29 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
Measured over From VX-880 infusion to end of study (at least 5 years)
+2 more outcomes measured
Conditions
Where it's being run
29 sites across 19 statesCanada4
United Kingdom3
California2
Illinois2
Pennsylvania2
France2
Saudi Arabia2
Florida1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Clinical history of T1D with \>=5 years of duration of insulin dependence
At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment
Stable diabetic treatment
Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study
Exclusion
Prior islet cell transplant, organ transplant, or cell therapy
What this trial measures
- Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)From VX-880 infusion to end of study (at least 5 years)
- Parts B and C: Proportion of Participants who are Insulin Independent with Absence of Severe Hypoglycemic Events (SHEs)1 year after achieving insulin independence (following VX-880 infusion)
- Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)From VX-017 infusion to end of study (at least 5 years)